Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of AVP-786 for agitation in Alzheimer's disease dementia
2020-000799-39Phase 3Active
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Dec 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing AVP-786 with Placebo (2 arms). Primary endpoint: Change from baseline to end of efficacy period in Cohen-Mansfield Agitation Inventory total score. Started Dec 2020; status: active.
02
Drugs
deudextromethorphan
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2020-000799-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000799-39.